Patents by Inventor Qingqi Chen
Qingqi Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11131668Abstract: Nanotube based lateral flow test device described herein is a lateral flow based diagnostic device, which uses arrays of fragments of single wall carbon nanotubes as sensor to detect the biomarkers at ultralow concentration (below picogram per milliliter). The device is consisted of the following components: (1) a lateral flow strip which typically is consisted of a backing film laminated with conjugate/sample pads, nitrocellulose membrane, wicking pad, (2) the arrays of single wall carbon nanotube conjugate with antibody which is immobilized on the membrane of the lateral flow device as the test line, (3) pairs of micro-electrode are installed on top part of the cassette, (4) a cassette which holds the lateral flow strip. The device can be used in clinical environments for biomarker detection.Type: GrantFiled: September 21, 2018Date of Patent: September 28, 2021Assignee: BioMedomics, Inc.Inventors: Xue-feng Wang, Qingqi Chen
-
Publication number: 20190018010Abstract: Nanotube based lateral flow test device described herein is a lateral flow based diagnostic device, which uses arrays of fragments of single wall carbon nanotubes as sensor to detect the biomarkers at ultralow concentration (below picogram per milliliter). The device is consisted of the following components: (1) a lateral flow strip which typically is consisted of a backing film laminated with conjugate/sample pads, nitrocellulose membrane, wicking pad, (2) the arrays of single wall carbon nanotube conjugate with antibody which is immobilized on the membrane of the lateral flow device as the test line, (3) pairs of micro-electrode are installed on top part of the cassette, (4) a cassette which holds the lateral flow strip. The device can be used in clinical environments for biomarker detection.Type: ApplicationFiled: September 21, 2018Publication date: January 17, 2019Inventors: Xue-feng Wang, Qingqi Chen
-
Patent number: 10082501Abstract: Nanotube based lateral flow test device described herein is a lateral flow based diagnostic device, which uses arrays of fragments of single wall carbon nanotubes as sensor to detect the biomarkers at ultralow concentration (below picogram per milliliter). The device is consisted of the following components: (1). an lateral flow strip which typically is consisted of a backing film laminated with conjugate/sample pads, nitrocellulose membrane, wicking pad, (2). the arrays of single wall carbon nanotube conjugate with antibody which is immobilized on the membrane of the lateral flow device as the test line, (3). pairs of micro-electrode are installed on top part of the cassette, (4). a cassette which holds the lateral flow strip. The device can be used in clinical environments for biomarker detection.Type: GrantFiled: July 3, 2013Date of Patent: September 25, 2018Assignee: BioMedomics, Inc.Inventors: Xue-feng Wang, Qingqi Chen
-
Publication number: 20170044121Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: October 31, 2016Publication date: February 16, 2017Applicant: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 9481660Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: April 7, 2014Date of Patent: November 1, 2016Assignee: ERimos Pharmaceuticals, LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Publication number: 20150374709Abstract: Disclosed are nordihydroguaiarctic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: June 29, 2015Publication date: December 31, 2015Inventors: Qingqi CHEN, Rocio Alejandra LOPEZ, Jonathan Daniel HELLER, Amanda Jean MORRIS
-
Patent number: 9067875Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: May 14, 2012Date of Patent: June 30, 2015Assignee: ERIMOS PHARMACEUTICALS LLCInventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20150141417Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: May 14, 2012Publication date: May 21, 2015Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20140287526Abstract: Nanotube based lateral flow test device described herein is a lateral flow based diagnostic device, which uses arrays of fragments of single wall carbon nanotubes as sensor to detect the biomarkers at ultralow concentration (below picogram per milliliter). The device is consisted of the following components: (1). an lateral flow strip which typically is consisted of a backing film laminated with conjugate/sample pads, nitrocellulose membrane, wicking pad, (2). the arrays of single wall carbon nanotube conjugate with antibody which is immobilized on the membrane of the lateral flow device as the test line, (3). pairs of micro-electrode are installed on top part of the cassette, (4). a cassette which holds the lateral flow strip. The device can be used in clinical environments for biomarker detection.Type: ApplicationFiled: July 3, 2013Publication date: September 25, 2014Inventors: Xue-Feng Wang, Qingqi Chen
-
Publication number: 20140221384Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: ERIMOS PHARMACEUTICALS LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8691845Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: July 30, 2012Date of Patent: April 8, 2014Assignee: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Publication number: 20140094041Abstract: The invention is provided with a contact system (25) which comprises a first conductor (5) with a radial contact surface (6, 6?), a second conductor (8) with an axial contact surface (7) and a contact member (24) mounted on the first conductor (5) in radially displaceable mode relative to the first conductor (5). The contact member (24) comprises a first contact portion (15) and a second contact portion (16) electrically connected to each other. The first contact portion (15) of the contact member (24) contacts with the radial contact surface (6, 6?) of the first conductor (5) and is radially movable relative to the first conductor (5), and the second contact portion (16) of the contact member (24) contacts with the axial contact surface (7) of the second conductor (8) and is axially movable relative to the second conductor (8).Type: ApplicationFiled: September 27, 2013Publication date: April 3, 2014Applicant: EATON CORPORATIONInventors: Qingqi Chen, Francois J. Marchand, Lihua Bao
-
Publication number: 20130303531Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: May 14, 2012Publication date: November 14, 2013Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20130053378Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: July 30, 2012Publication date: February 28, 2013Applicant: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Jonathan Daniel Heller, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8232277Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: October 2, 2007Date of Patent: July 31, 2012Assignee: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Jonathan Daniel Heller, Rocio Alejandra Lopez, Amanda Jean Morris
-
Patent number: 8178527Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: GrantFiled: October 2, 2007Date of Patent: May 15, 2012Assignee: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20120029216Abstract: A manufacturing process for making terameprocol (1) which includes the following reaction scheme, wherein a first general reaction is the formation of a furan intermediate (39) and a second general reaction is the ring-reduction and ring-opening of the furan intermediate (39) to form the terameprocol (1):Type: ApplicationFiled: July 31, 2009Publication date: February 2, 2012Applicant: Erimos Pharmaceuticals LLCInventors: Qingqi Chen, Jessica Andrea Blomburg
-
Publication number: 20100022528Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: October 2, 2007Publication date: January 28, 2010Applicant: ERIMOS PHARMACEUTICALS LLC.Inventors: Qingqi Chen, Rocio Alejandra Lopez, Jonathan Daniel Heller, Amanda Jean Morris
-
Publication number: 20090306070Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.Type: ApplicationFiled: October 2, 2007Publication date: December 10, 2009Applicant: Erimos Pharmaceuticals LLCInventors: Jonathan Daniel Heller, Qingqi Chen, Rocio Alejandra Lopez, Amanda Jean Morris
-
Publication number: 20060029586Abstract: The invention provides bioconjugates of the formula: in which A is an active agent comprising an active hydroxy or amino functionality and B is a biopolymer comprising an active hydroxy or amino functionality, and X1 and X2 are independently N or O, and R is substituted alkyl or unsubstituted alkyl or unsubstituted or substituted heteroalkyl from 1 to about 30 atoms in length. The biopolymer may for instance be a transport protein or an antibody directed to a transport protein (e.g., a p97 protein or antibody thereto). The active agent may be a therapeutic agent such as a chemotherapeutic agent or an antineoplastic agent or an enzyme. The bioconjugates find therapeutic usages according to the therapeutic indications of the active agent. Methods of making the bioconjugates and bifunctional isocyanate cross linking reagents of use in making such bioconjugates are provided.Type: ApplicationFiled: January 14, 2005Publication date: February 9, 2006Inventors: Qingqi Chen, Damian Sowa, Reinhard Gabathuler